BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Amundi | 221,668 | $15,026,874 | 0.01% |
| Banque Cantonale Vaudoise | 2,000 | $136 | 0.01% |
| Cetera Investment Advisers | 11,148 | $758,841 | 0.01% |
| Rafferty Asset Management, LLC | 16,426 | $1,118,118 | 0.01% |
| PANAGORA ASSET MANAGEMENT INC | 15,913 | $1,083,198 | 0.01% |
| abrdn plc | 38,412 | $2,614,705 | 0.01% |
| Ensign Peak Advisors, Inc | 45,870 | $3,122,372 | 0.01% |
| Lindbrook Capital, LLC | 744 | $50,644 | 0.01% |
| OSSIAM | 4,850 | $330,139 | 0.01% |
| TEACHER RETIREMENT SYSTEM OF TEXAS | 12,197 | $830 | 0.01% |
| Trexquant Investment LP | 3,589 | $244,303 | 0.01% |
| Pacer Advisors, Inc. | 23,599 | $1,606,384 | 0.01% |
| CIBC WORLD MARKETS CORP | 8,690 | $591,528 | 0.01% |
| AQR Capital Management | 41,615 | $2,832,744 | 0.01% |
| ProShare Advisors LLC | 28,206 | $1,919,982 | 0.01% |
| CIBC Asset Management Inc | 22,250 | $1,514,558 | 0.01% |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 140,622 | $9,572,140 | 0.01% |
| State of Tennessee, Treasury Department | 23,621 | $1,607,882 | 0.01% |
| PATHSTONE FAMILY OFFICE, LLC | 10,936 | $744,419 | 0.01% |
| Bridgewater Associates | 12,318 | $838,486 | 0.01% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.